SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Zepp Health Corporation (ZEPP) has a negative trailing P/E of -0.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -360.84%.
Criteria proven by this page:
- VALUE (20/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -0.3); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -360.84%); analyst consensus target implies downside from the current price ($12.00, 15%).
- Trailing Earnings Yield -360.84% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
- Analyst consensus target $12.00 (-15% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 26/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
20/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ZEPP
Valuation Multiples
P/E (TTM)-0.3
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.05
P/S Ratio0.62
EV/EBITDA-10.5
Per Share Data
EPS (TTM)$-289.80
Book Value / Share$1,511.76
Revenue / Share$1,858.93
FCF / Share$0.00
Yields & Fair Value
Earnings Yield-360.84%
Dividend Yield0.00%
SharesGrow IV$152.78 (+982%)
Analyst Target$12.00 (-15%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
185.3 |
-2.26 |
13.71 |
2.85 |
- |
| 2017 |
26.6 |
-0.22 |
7.47 |
2.18 |
- |
| 2018 |
10.7 |
0.01 |
2.08 |
1.00 |
- |
| 2019 |
9.0 |
0.03 |
2.08 |
0.89 |
0.09% |
| 2020 |
22.2 |
-0.24 |
1.76 |
0.79 |
- |
| 2021 |
14.9 |
-0.38 |
0.69 |
0.33 |
- |
| 2022 |
-2.1 |
0.01 |
0.23 |
0.15 |
1.02% |
| 2023 |
-2.8 |
0.10 |
0.25 |
0.25 |
- |
| 2024 |
-0.6 |
0.00 |
0.17 |
0.23 |
- |
| 2025 |
-0.7 |
0.00 |
0.12 |
0.10 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.80 |
$1.56B |
$23.95M |
1.5% |
| 2017 |
$3.12 |
$2.05B |
$167.68M |
8.2% |
| 2018 |
$24.16 |
$3.65B |
$340.05M |
9.3% |
| 2019 |
$35.96 |
$5.81B |
$575.2M |
9.9% |
| 2020 |
$14.04 |
$6.43B |
$228.75M |
3.6% |
| 2021 |
$5.80 |
$6.25B |
$95.92M |
1.5% |
| 2022 |
$-19.92 |
$4.14B |
$-306.66M |
-7.4% |
| 2023 |
$-13.96 |
$2.5B |
$-212.12M |
-8.5% |
| 2024 |
$-18.56 |
$182.6M |
$-75.73M |
-41.5% |
| 2025 |
$-283.04 |
$1.82B |
$-280.92M |
-15.5% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.07 |
$-0.07 – $-0.07 |
$2.17B |
$2.17B – $2.17B |
1 |
